Illumina Non-GAAP EPS of $0.14 misses by $0.05, revenue of $1.08B beats by $10M
Illumina press release (NASDAQ:ILMN): Q4 Non-GAAP EPS of $0.14  misses by $0.05.
Revenue of $1.08B (-9.6% Y/Y)  beats by $10M.
Capital expenditures for free cash flow purposes were $286 million for fiscal year 2022.
Cash flow provided by operations was $392 million, compared to $545 million in the prior year.

Free cash flow (cash flow provided by operations less capital expenditures) was $106 million for the year, compared to $337 million in the prior year.
Partnered with Amgen, a global biopharmaceutical company, to whole-genome sequence a cohort of approximately 35,000 DNA samples made up of DNA from African Americans, who are currently underrepresented in research for the clinical applications of genomics, including drug target discovery.
Achieved the highest score out of 72 companies in its industry in the S&P Global Corporate Sustainability Assessment, also known as the Dow Jones Sustainability Index.

Outlook: For fiscal year 2023, expect revenue to grow 7% to 10% compared to fiscal year 2022, GAAP diluted earnings per share of $0.03 to $0.28, and non-GAAP diluted earnings per share of $1.25 to $1.503
Shares -2.19%.